Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Most loved Amusement Park Firecrackers Show: Which One Lights Up Your Evening? - 2What an expert on the gut microbiome eats in a day
- 3Orcas seen hunting great white sharks to eat their livers in drone footage recorded in Mexico
- 4NASA's Artemis astronauts enter final preparations for Moon mission
- 5Smoking rate among US adults drops to record low as vape use rises, CDC report finds
- Step by step instructions to Deal with Your Time While Chasing after an Internet based Degree
- Fundamental Monetary Guidance for Going into Business
- Rick Steves Doesn't Want You Overlooking This Food Spot While In France
- NASA wants to build a base on the Moon by the 2030s – how and why it plans to build up to a long-term lunar presence
- Experience Unrivaled Sound: Top Speakers You Really want to Hear
- The Best Games Crossroads in History
- What is ‘Auld Lang Syne’? Why we sing this song at midnight on New Year’s Eve.
- Flourishing as a Charitable Pioneer: Individual Encounters in Generosity
- 'We need everyone,' wounded reservist urges Knesset panel to advance haredi draft law
